News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Arianna Cavalli

Articles by Arianna Cavalli

64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

BySusan Laura Jao,Fardeen Bhimani,Arianna Cavalli,Bryan Harmon,Maureen McEvoy,Ethan Ravetch,Michelle Sheckley,Anjuli Gupta,Sheldon Feldman

May 13th 2025

68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

ByArianna Cavalli,Susan Laura Jao,Skylar Harbour,Melissa Rony,Sheldon Feldman,Maureen McEvoy

May 10th 2025

40 Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis

ByArianna Cavalli,Fardeen Bhimani,Lesley G. Coe,Liane N. Obaid,Anjuli Gupta,Jessica Pastoriza,Sheldon Feldman,Maureen McEvoy

June 8th 2024

49 The Influence of Race on Complications in Breast Conservation Surgery: A Single Institution Study

ByLiane N. Obaid,Janice S. Zhang,Grace Y. Lee,Fardeen Bhimani,Lesley G. Coe,Arianna Cavalli,Anjuli Gupta,Jessica Pastoriza,Sheldon Feldman,Maureen McEvoy

May 22nd 2024

56 Predictive Factors Correlating With Pathologic Complete Response Rates in Racially Diverse, Minority Populations Receiving Neoadjuvant Therapy for HR+/HER2– Breast Cancer

ByLesley G. Coe,Fardeen Bhimani,Liane N. Obaid,Arianna Cavalli,Anjuli Gupta,Jessica Pastoriza,Sheldon Feldman,Maureen McEvoy

May 14th 2024

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC

TIP127 TroFuse-012: A Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab Vs Treatment of Physician’s Choice in Participants With Triple-Negative Breast Cancer who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery